Tag:
R&D;
Latest Headlines
Latest Headlines
Strimvelis to be the start of a whole new gene therapy platform for GSK and partners
GlaxoSmithKline and its Italian research partners are plotting major new European research hubs with future growth in gene therapies and beyond after the CHMP recommended its new "bubble boy" drug for approval in Europe on Friday.
IBM plans $150M Italian investment as Watson Health goes global
IBM is to establish a beachhead for its European health expansion plans in Italy. The move takes the form of a planned $150 million investment in a Watson Health European Center of Excellence in Milan, which IBM sees acting as the basis of its attempts to grow its healthcare and life science R&D; business in the region.
UPDATED: Did Clovis play a deceptive game with rociletinib data in leadup to its PhIII stunner?
New analysis published in the Annals of Oncology raises serious questions about the truthfulness and timing involved in the way Clovis Oncology corrected pivotal data on its cancer drug rociletinib.
Step right up and place your bets on who might buy Medivation
AstraZeneca, Roche and Sanofi are just three Big Pharma names being touted as possible suitors for the struggling biotech Medivation--but analysts warn it won't come cheap, or easy.
DOD awards UC Irvine $8M to develop Q fever vaccine
While Coxiella burnetii, the bacterium that causes Q fever, is rarely fatal in humans, it has been aerosolized for use as a biological weapon before. A University of California, Irvine, team won $8 million from the DOD's Defense Threat Reduction Agency to develop a new vaccine against the bacterium.
Upstart Zavante raises $45M, takes aim at a pivotal antibiotic study
San Diego-based Zavante Therapeutics has raised $35 million--adding it to an additional $10 million from convertible debt for the Series A round--to back a pivotal study aimed at U.S. approval of an aging antibiotic.
Sanofi Pasteur releases early results from next-gen flu vax tech
Sanofi Pasteur and the University of Georgia this week talked up details of a next-gen flu vaccine strategy that the pair hopes can build on the strength of current vaccines but broaden protection to avoid the problems associated with strain drift.
MD Anderson Cancer Center adds to its growing life science universe with Tesaro deal
Texas is adding more eggs to its incubator as cancer biopharma Tesaro has inked a deal with UT's MD Anderson Cancer Center for new immuno-oncology targets.
Alexza literally at end of days as its cash pile set to run out by May
The alarm bells are ringing at Alexza Pharmaceuticals as the small biotech announced a weak set of financials and the stark warning that without help, it will likely shut down operations by the summer.
Sanofi recruits AstraZeneca research veteran to 'rejuvenate' its R&D; division
Sanofi has poached Dr. Yong-Jun Liu as its new head of research from MedImmune as it looks to beef up its early-stage pipeline and senior R&D; leadership team.
